KTTA Insider Trading

Insider Ownership Percentage: 14.10%
Insider Buying (Last 12 Months): $12,900.00
Insider Selling (Last 12 Months): $0.00

Pasithea Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Pasithea Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pasithea Therapeutics Share Price & Price History

Current Price: $7.11
Price Change: Price Decrease of -0.04 (-0.56%)
As of 04/19/2024 10:57 AM ET

This chart shows the closing price history over time for KTTA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Pasithea Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/2/2023Lawrence SteinmanDirectorBuy1,500$8.60$12,900.0066,358View SEC Filing Icon  
10/17/2022David DelaneyMajor ShareholderBuy50$22.20$1,110.0011,376View SEC Filing Icon  
9/28/2022Eric ShahinianMajor ShareholderBuy2,882$23.80$68,591.6089,085View SEC Filing Icon  
8/29/2022Eric ShahinianMajor ShareholderBuy250$23.40$5,850.0080,866View SEC Filing Icon  
8/19/2022Avi GellerMajor ShareholderBuy2,732$26.00$71,032.002,732View SEC Filing Icon  
8/17/2022Eric ShahinianMajor ShareholderBuy7,788$24.20$188,469.6080,566View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Pasithea Therapeutics (NASDAQ:KTTA)

23.92% of Pasithea Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KTTA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Pasithea Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/10/2023K2 Principal Fund L.P.282,437$0.18M0.0%-42.6%0.966%Search for SEC Filing on Google Icon
11/15/2022Vanguard Group Inc.159,844$0.20M0.0%+104.6%0.599%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.56,583$74K0.0%+345.5%0.248%Search for SEC Filing on Google Icon
5/12/2022Mark Sheptoff Financial Planning LLC48,000$62K0.0%N/A0.210%Search for SEC Filing on Google Icon
2/11/2022K2 Principal Fund L.P.550,000$0.97M0.1%N/A4.164%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Securities LLC10,440$32K0.0%N/A0.080%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Pasithea Therapeutics logo
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Read More on Pasithea Therapeutics

Today's Range

Now: $7.11
Low: $7.11
High: $7.11

50 Day Range

MA: $7.32
Low: $5.80
High: $8.75

52 Week Range

Now: $7.11
Low: $5.25
High: $17.40


503 shs

Average Volume

9,844 shs

Market Capitalization

$7.39 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Pasithea Therapeutics?

Pasithea Therapeutics' top insider investors include:
  1. Eric Shahinian (Major Shareholder)
  2. Lawrence Steinman (Director)
  3. David Delaney (Major Shareholder)
  4. Avi Geller (Major Shareholder)
Learn More about top insider investors at Pasithea Therapeutics.